الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

american regent, inc. - tranexamic acid (unii: 6t84r30kc1) (tranexamic acid - unii:6t84r30kc1) - tranexamic acid 100 mg in 1 ml - tranexamic acid injection, usp is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. tranexamic acid injection is contraindicated: - in patients with subarachnoid hemorrhage. anecdotal experience indicates that cerebral edema and cerebral infarction may be caused by tranexamic acid injection in such patients. - in patients with active intravascular clotting [see warnings and precautions (5.1)] . - in patients with hypersensitivity to tranexamic acid or any of the ingredients [ see warnings and precautions (5.4)] . risk summary available data from published studies, case series and case reports with tranexamic acid use in pregnant women in the second and third trimester and at the time of delivery have not clarified whether there is a drug-associated risk of miscarriage or adverse maternal or fetal outcomes. there are 2 (0.02%) infant cases with structural abnormalities that re

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

heritage pharmaceuticals labs inc. d/b/a avet pharmaceuticals labs inc. - tranexamic acid (unii: 6t84r30kc1) (tranexamic acid - unii:6t84r30kc1) - tranexamic acid 1 g in 10 ml - tranexamic acid injection, usp is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. tranexamic acid injection, usp is contraindicated: -   in patients with subarachnoid hemorrhage. anecdotal experience indicates that cerebral edema and cerebral infarction may be caused by tranexamic acid injection in such patients. -   in patients with active intravascular clotting [see warnings and precautions ( 5.1)] . -   in patients with hypersensitivity to tranexamic acid or any of the ingredients [see warnings and precautions ( 5.4 )]. risk summary available data from published studies, case series and case reports with tranexamic acid use in pregnant women in the second and third trimester and at the time of delivery have not clarified whether there is a drug-associated risk of miscarriage or adverse maternal or fetal outcomes. there are 2 (0.02%) infant cases with structural abnormal

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

zydus pharmaceuticals (usa) inc. - tranexamic acid (unii: 6t84r30kc1) (tranexamic acid - unii:6t84r30kc1) - tranexamic acid 100 mg in 1 ml - tranexamic acid injection is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. tranexamic acid injection is contraindicated: - in patients with subarachnoid hemorrhage. anecdotal experience indicates that cerebral edema and cerebral infarction may be caused by tranexamic acid injection in such patients. - in patients with active intravascular clotting [see warnings and precautions (5.1)] . - in patients with hypersensitivity to tranexamic acid or any of the ingredients [see warnings and precautions (5.4)] . risk summary available data from published studies, case series and case reports with tranexamic acid use in pregnant women in the second and third trimester and at the time of delivery have not clarified whether there is a drug-associated risk of miscarriage or adverse maternal or fetal outcomes. there are 2 (0.02%) infant cases with structural abnormalities that result

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - tranexamic acid, quantity: 500 mg - injection, intravenous infusion - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - intravenous administration,adults,for the reduction of peri- and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty.,paediatrics,for the reduction of peri- and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

luminarie pty ltd - tranexamic acid, quantity: 100 mg/ml - injection, solution - excipient ingredients: water for injections - adults,for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty.,paediatrics,for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - tranexamic acid, quantity: 500 mg - tablet, film coated - excipient ingredients: titanium dioxide; microcrystalline cellulose; macrogol 8000; colloidal anhydrous silica; povidone; purified talc; vanillin; croscarmellose sodium; magnesium stearate; basic butylated methacrylate copolymer - oral administration hereditary angioneurotic oedema. short term use in the treatment of hyphaema and in patients with established coagulopathies who are undergoing minor surgery. menorrhagia.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - tranexamic acid, quantity: 500 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; purified talc; titanium dioxide; microcrystalline cellulose; vanillin; macrogol 8000; colloidal anhydrous silica; povidone; magnesium stearate; basic butylated methacrylate copolymer - oral administration hereditary angioneurotic oedema. short term use in the treatment of hyphaema and in patients with established coagulopathies who are undergoing minor surgery. menorrhagia.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - tranexamic acid, quantity: 500 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; purified talc; povidone; macrogol 8000; titanium dioxide; colloidal anhydrous silica; magnesium stearate; vanillin; basic butylated methacrylate copolymer - oral administration hereditary angioneurotic oedema. short term use in the treatment of hyphaema and in patients with established coagulopathies who are undergoing minor surgery. menorrhagia.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

steriscience pty ltd - tranexamic acid, quantity: 500 mg - injection, solution - excipient ingredients: water for injections - intravenous administration,adults for the reduction of peri- and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty.,paediatrics for the reduction of peri- and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - tranexamic acid, quantity: 500 mg - injection, solution - excipient ingredients: water for injections - intravenous administration,adults for the reduction of peri- and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty.,paediatrics for the reduction of peri- and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery.